Golden Matthew R, Workowski Kimberly A, Bolan Gail
Center for AIDS and STD, University of Washington, Seattle.
Public Health - Seattle & King County, Washington.
J Infect Dis. 2017 Jul 15;216(suppl_2):S420-S426. doi: 10.1093/infdis/jix200.
Although Mycoplasma genitalium is increasingly recognized as a sexually transmitted pathogen, at present there is no defined public health response to this relatively newly identified sexually transmitted infection. Currently available data are insufficient to justify routinely screening any defined population for M. genitalium infection. More effective therapies, data on acceptability of screening and its impact on clinical outcomes, and better information on the natural history of infection will likely be required before the value of potential screening programs can be adequately assessed. Insofar as diagnostic tests are available or become available in the near future, clinicians and public health agencies should consider integrating M. genitalium testing into the management of persons with sexually transmitted infection (STI) syndromes associated with the infection (ie urethritis, cervicitis, and pelvic inflammatory disease) and their sex partners. Antimicrobial-resistant M. genitalium is a significant problem and may require clinicians and public health authorities to reconsider the management of STI syndromes in an effort to prevent the emergence of ever more resistant M. genitalium infections.
尽管生殖支原体越来越被认为是一种性传播病原体，但目前对于这种相对新发现的性传播感染尚无明确的公共卫生应对措施。目前可得的数据不足以支持对任何特定人群进行生殖支原体感染的常规筛查。在能够充分评估潜在筛查项目的价值之前，可能需要更有效的治疗方法、关于筛查可接受性及其对临床结果影响的数据，以及关于感染自然史的更好信息。就目前已有或在不久的将来会有的诊断检测而言，临床医生和公共卫生机构应考虑将生殖支原体检测纳入对患有与该感染相关的性传播感染（STI）综合征（即尿道炎、宫颈炎和盆腔炎）的患者及其性伴侣的管理中。耐抗菌药物的生殖支原体是一个重大问题，可能需要临床医生和公共卫生当局重新考虑性传播感染综合征的管理，以努力防止出现耐药性更强的生殖支原体感染。
